文献速递胃肠动力与功能性疾病消化内镜

日本多中心前瞻性研究:经口内镜下肌切开术治疗贲门失弛缓症

Peroral endoscopic myotomy for achalasia: a prospective multicenter study in Japan.
PubMed 文献 · Gastrointest Endosc · 2019-11-21

该研究为日本8家机构的前瞻性单臂试验,纳入233例接受经口内镜下肌切开术(POEM)的贲门失弛缓症患者。符合纳入标准的207例患者中,1年时Eckardt评分≤3定义的疗效率为97.4%(95%CI 95.3%-99.7%),Eckardt评分从术前6.6±2.0显著降至1.1±1.1。结论认为POEM安全且至少1年内高度有效。

要点

  • POEM治疗贲门失弛缓症1年疗效率达97.4%(95%CI 95.3%-99.7%)
  • 手术相关不良事件发生率为10.3%,均无需外科干预
  • 术后反流性食管炎、严重反流性食管炎及症状性GERD分别占54.2%、5.6%、14.7%

核心结论

  • 日本前瞻性多中心研究显示POEM治疗贲门失弛缓症疗效高于既往前瞻性多中心研究结果。
  • POEM至少1年内安全且高度有效。

研究设计与样本

  • 前瞻性单臂试验,2016年4月至2018年3月在日本8家机构开展。
  • 共233例贲门失弛缓症患者接受POEM,其中207例符合纳入标准。
  • 术后3个月及至1年时进行再评估。

主要发现

  • 233例中手术相关不良事件24例(10.3%),均无需外科干预。
  • 207例符合纳入标准患者1年时Eckardt评分≤3的疗效率为97.4%(95%CI 95.3%-99.7%)。
  • Eckardt评分从术前6.6±2.0显著降至术后1年1.1±1.1。
  • 术后反流性食管炎占54.2%,严重反流性食管炎占5.6%,症状性GERD占14.7%,21.1%使用质子泵抑制剂。

关键数值与推荐

  • 疗效定义为术后1年Eckardt评分≤3。
  • 手术相关不良事件发生率10.3%。
  • 术后反流性食管炎发生率54.2%,严重反流性食管炎5.6%,症状性GERD 14.7%。
  • 质子泵抑制剂使用率21.1%。

临床怎么用

  • POEM可作为贲门失弛缓症安全且高效的治疗选择,至少1年疗效维持。
  • 术后需关注反流性食管炎及症状性GERD,必要时使用质子泵抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Peroral endoscopic myotomy (POEM) is an available treatment modalities for achalasia. The reported efficacy of POEM in the only prospective multicenter study was 82%; however, a retrospective multicenter study in Japan reported a higher efficacy rate of 95%. The aim of this study was to prospectively verify treatment outcomes after POEM at multiple facilities in Japan. METHODS: This was a prospective single-arm trial of POEM for achalasia at 8 facilities in Japan between April 2016 and March 2018 to evaluate its safety and efficacy. Patients were re-evaluated at 3 months and up to 1 year after POEM. RESULTS: Among the 233 patients with achalasia who underwent POEM, procedure-related adverse events occurred in 24 patients (10.3%), none of whom required surgical intervention. In the 207 patients satisfying the inclusion criteria, the efficacy rate of POEM, defined by an Eckardt score ≤3 at 1 year, was 97.4% (95% CI, 95.3%-99.7%). The Eckardt score decreased significantly from 6.6 ± 2.0 preoperatively to 1.1 ± 1.1, 1 year after POEM. Postoperative reflux esophagitis, severe reflux esophagitis, and symptomatic GERD were reported in 54.2%, 5.6%, and 14.7%, respectively, and proton pump inhibitors were administered in 21.1%. CONCLUSIONS: Our prospective multicenter study in Japan showed greater efficacy of POEM for achalasia compared with the results of a previous prospective multicenter study. POEM is safe and highly effective for at least 1 year. (Clinical trial registration number: UMIN 000021550.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Shiwaku H, Inoue H, Sato H, et al. Peroral endoscopic myotomy for achalasia: a prospective multicenter study in Japan. Gastrointest Endosc. 2019. PMID: 31759035. doi:10.1016/j.gie.2019.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。